(Q35082619)

English

Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss (English)

1 reference

Europe PubMed Central

6 August 2017

Alberto Massocco

object named as

Alberto Massocco

7

0 references

Erminia Manfrin

object named as

Erminia Manfrin

8

0 references

Giuseppe Zamboni

object named as

Giuseppe Zamboni

10

0 references

author name string

Giuseppe Bogina

1

1 reference

Europe PubMed Central

6 August 2017

Laura Bortesi

2

1 reference

Europe PubMed Central

6 August 2017

Marcella Marconi

3

1 reference

Europe PubMed Central

6 August 2017

Marco Venturini

4

1 reference

Europe PubMed Central

6 August 2017

Gianluigi Lunardi

5

1 reference

Europe PubMed Central

6 August 2017

Francesca Coati

6

1 reference

Europe PubMed Central

6 August 2017

Cristina Pegoraro

9

1 reference

Europe PubMed Central

6 August 2017

publication date

4 June 2011

1 reference

Europe PubMed Central

6 August 2017

Virchows Archiv

1 reference

Europe PubMed Central

6 August 2017

459

1 reference

Europe PubMed Central

6 August 2017

1

1 reference

Europe PubMed Central

6 August 2017

1-10

1 reference

Europe PubMed Central

6 August 2017

https://scigraph.springernature.com/pub.10.1007/s00428-011-1097-7

0 references

Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Metastasis: from dissemination to organ-specific colonization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

HER-2/neu diagnostics in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

HER2 gene status in primary breast cancers and matched distant metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

8 July 2018

Should liver metastases of breast cancer be biopsied to improve treatment choice?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Impact of metastatic estrogen receptor and progesterone receptor status on survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

erbB-2 (HER-2) and breast cancer progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Progesterone receptor status of breast cancer metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression*.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128259

27 September 2018

Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-011-1097-7

21 January 2018

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Change of HER-2/neu status in a subset of distant metastases from breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estrogen and progesterone receptor concordance between primary and recurrent breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00428-011-1097-7

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35082619&oldid=1978558352"